2020
COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network
Network I, Antonoff M, Backhus L, Boffa DJ, Broderick SR, Brown LM, Carrott P, Clark JM, Cooke D, David E, Facktor M, Farjah F, Grogan E, Isbell J, Jones DR, Kidane B, Kim AW, Keshavjee S, Krantz S, Lui N, Martin L, Meguid RA, Meyerson SL, Mullett T, Nelson H, Odell DD, Phillips JD, Puri V, Rusch V, Shulman L, Varghese TK, Wakeam E, Wood DE. COVID-19 guidance for triage of operations for thoracic malignancies: A consensus statement from Thoracic Surgery Outcomes Research Network. Journal Of Thoracic And Cardiovascular Surgery 2020, 160: 601-605. PMID: 32689703, PMCID: PMC7146695, DOI: 10.1016/j.jtcvs.2020.03.061.Peer-Reviewed Original ResearchMeSH KeywordsBetacoronavirusClinical Decision-MakingConsensusCoronavirus InfectionsCOVID-19Delivery of Health Care, IntegratedHealth Services Needs and DemandHost Microbial InteractionsHumansNeeds AssessmentOccupational HealthPandemicsPatient SafetyPatient SelectionPneumonia, ViralRisk AssessmentRisk FactorsSARS-CoV-2Thoracic NeoplasmsThoracic Surgical ProceduresTime-to-TreatmentTriageSurgeon's Perspective to Local Therapy in Oligometastatic Cancer.
Boffa DJ. Surgeon's Perspective to Local Therapy in Oligometastatic Cancer. The Cancer Journal 2020, 26: 149-155. PMID: 32205540, DOI: 10.1097/ppo.0000000000000441.Peer-Reviewed Original Research
2019
Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma
Klemen ND, Wang M, Feingold PL, Cooper K, Pavri SN, Han D, Detterbeck FC, Boffa DJ, Khan SA, Olino K, Clune J, Ariyan S, Salem RR, Weiss SA, Kluger HM, Sznol M, Cha C. Patterns of failure after immunotherapy with checkpoint inhibitors predict durable progression-free survival after local therapy for metastatic melanoma. Journal For ImmunoTherapy Of Cancer 2019, 7: 196. PMID: 31340861, PMCID: PMC6657062, DOI: 10.1186/s40425-019-0672-3.Peer-Reviewed Original ResearchConceptsThree-year progression-free survivalProgression-free survivalDisease-specific survivalFive-year disease-specific survivalPatterns of failureDurable progression-free survivalLocal therapyStereotactic body radiotherapyMetastatic melanomaNew metastasesPatient selectionIndependent radiological reviewOngoing complete responseResultsFour hundred twentyEvidence of diseaseCNS metastasisCPI treatmentImmunotherapy failureCheckpoint inhibitorsMost patientsProgressive diseaseRadiological reviewComplete responsePD-1PD-L1